Registration Deadline:
Vanderbilt Contact:
More Information:
Explore other Industry Opportunities:
A publicly traded, fully integrated mid-cap biopharmaceutical company with commercial products providing over $1 billion in annual revenue is seeking therapeutic candidates for use in central and peripheral nervous system diseases. The company is looking for novel therapeutics that are new chemical entities, ideally with a composition of matter patent filed in the last 5 years or with potential for similarly meaningful patent protection. This conscientious company aims to bring assets in-house and develop them to their full potential.
Approaches of interest
- Open to a range of neurological and psychiatric diseases
- For neurodegenerative diseases, non-disease modifying therapeutics and treatments for management of neuropsychiatric symptoms (agitation/aggression, apathy, fatigue, psychosis)
- Modalities include small molecules, peptides, biologics, and RNA-based therapies developed by biopharma companies
- Potential first-in-class therapeutics prioritized; best-in-class therapeutics considered with strong rationale
Out of scope
- Therapeutics with disease-modifying action in neurodegenerative diseases
- Nociceptive pain, MS, acute insult/injury indications (stroke, TBI), nicotine use disorder/smoking cessation
- Diseases with fewer than 10,000 US patients
- Repurposed/reformulated therapeutics
- Diagnostics, medical devices, and digital therapeutics
Developmental stage of interest: Opportunities from nominated drug candidate through completion of Phase 1, with therapeutics having at least in vivo validation as highest priority.
Please note: Summaries generated by AI. Please see attached documentation or email Cameron Sargent, CTTC Licensing Officer, for more information. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.